

November 18, 2021

To,
SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sir,

**Sub :- Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation,
2015 – S&P Global Ratings**

With reference to the subject mentioned above, kindly find enclosed rating research update issued by S&P Global Ratings for your reference.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited



Harish Kuber
Company Secretary & Compliance Officer



Encl: S&P Global Ratings

Research Update:

Glenmark Pharmaceuticals Upgraded To 'BB' On Expected Maintenance Of Lower Leverage; Outlook Stable

November 18, 2021

Rating Action Overview

- Glenmark Pharmaceuticals Ltd.'s debt is likely to decline by about 25% in fiscal 2022 (year ending March 31, 2022) given management's commitment to maintain lower leverage following a recent equity raising at its subsidiary.
- We expect the India-based pharmaceutical player to maintain conservative debt levels given limited upcoming capital investments and healthy free operating cash flow. This should boost the company's ratio of funds from operations (FFO) to debt to 35%-40% in fiscal 2022.
- Therefore, we raised our long-term issuer credit rating on Glenmark to 'BB' from 'BB-'.
- The stable outlook reflects our view that Glenmark will maintain its financial policy such that its FFO-to-debt ratio will remain comfortably above 30%.

PRIMARY CREDIT ANALYST

Shruti Zatakia
Singapore
+ 65 6216 1094
shruti.zatakia
@spglobal.com

SECONDARY CONTACT

Neel Gopalakrishnan
Singapore
+ 65-6239-6385
neel.gopalakrishnan
@spglobal.com

Rating Action Rationale

Glenmark will likely prioritize debt reduction over the next 12-18 months. We expect the company to repay up to Indian rupees (INR) 16 billion in debt during fiscal 2022 in line with management's commitment to deleverage. Glenmark's subsidiary, Glenmark Lifesciences Ltd., concluded its public equity offering in July 2021 and raised about INR15 billion. Subsequently, Glenmark repaid about INR11 billion of its outstanding borrowings. We believe Glenmark will direct its surplus operating cash flow over the next few quarters toward further debt reduction to meet its stated target. Thereafter, we expect the company's adjusted gross debt to remain stable at INR35 billion-INR40 billion over fiscals 2022 and 2023, compared with INR51 billion at the end of fiscal 2021.

Glenmark's healthy revenue growth and cost optimization measures, including reduced investments (measured as a percentage of revenues) in research and development (R&D), will bolster its operating cash flow. We estimate the company will generate INR12 billion-INR14 billion in operating cash flow annually over fiscals 2022 and 2023. Moreover, Glenmark has limited

upcoming capital investment requirements over this period. Capital spending of INR6 billion-INR7 billion annually should be restricted to maintenance and minor capacity enhancements--adequately covered by its operating cash flow, in our assessment.

We believe Glenmark will sustain its conservative policy on shareholder distributions and acquisitions over the next two years. Consolidation in the generics pharmaceutical industry could present opportunities for inorganic growth. Still, we do not expect Glenmark's management to adopt an acquisition-led growth policy that could stretch its credit metrics beyond our base-case estimate. The company has historically focused on organic growth--a trend that will likely continue.

New product launches and favorable operating conditions should support growth. In our view, Glenmark's revenue from India, Europe and other international markets will continue to rise over the next 12-18 months. India, the company's largest market, accounts for more than 30% of overall revenues and we expect revenue from the country to grow 15%-20% in fiscal 2022. Sales for the company's base portfolio of products across segments such as diabetes, consumer care, dermatology and respiratory will likely rise. However, stabilizing COVID-19 infection rates could lead to lower sales of FabiFlu (oral antiviral used to treat COVID-19 patients) in the coming quarters, with the medicine to account for about 10% of fiscal 2022 revenue from India.

New product launches such as Ryaltris (a nasal spray for treatment of symptoms associated with allergic rhinitis) in Russia will also support growth in international markets. Glenmark has filed 11 Abbreviated New Drug Applications with the U.S. Food and Drug Administration (FDA) over the first half of fiscal 2022 and the company is likely to file 18-20 such applications in the full fiscal year. However, competitive pressures and continued price erosion in the U.S. (25% of Glenmark's revenue) is likely to offset the growth from new product launches. Overall, we expect revenues to grow 9%-10% in fiscal 2022 and EBITDA margin to remain at 19%-19.5%.

Glenmark will likely remain prudent in managing debt maturities beyond fiscal 2022. The company's foreign currency convertible bonds (FCCBs) are due for redemption on July 28, 2022, amounting to about US\$97 million. We believe the company has adequate funding options to meet this maturity. These options include undrawn committed bank lines of about US\$100 million (maturing mid-2023) and available cash and short-term investments (about US\$190 million equivalent as of Sept. 30, 2021). Thereafter, the company's debt maturity profile remains fairly balanced with various external commercial borrowings of about US\$60 million due in fiscal 2023 and US\$130 million in fiscal 2024. We believe the company's improved financial strength and flexibility should aid its ability to effectively manage these maturities.

Outlook

The stable outlook on Glenmark reflects our view that the company will maintain a conservative financial policy, supported by healthy operating cash flow and limited capital investments. We expect the company's FFO-to-debt ratio will remain comfortably above 30% over this period.

Downside scenario

We are likely to lower our rating on Glenmark if the company undertakes higher capital spending than we anticipate, or if profitability declines as a result of business conditions or increased R&D investments. This would be indicated by the company's FFO-to-debt ratio falling below 30% on a sustained basis. We could also lower the rating if Glenmark's liquidity weakens materially.

Upside scenario

We could consider an upgrade if:

- Glenmark demonstrates a solid track record of consistent deleveraging aided by improving profitability and strong free operating cash flow generation, such that the company's FFO-to-debt ratio stays sustainably above 45%; and
- The company continues to build scale and improve its portfolio quality, strengthening its market position.

Demonstration of improved funding access would also be supportive of a higher rating.

Company Description

Glenmark is an India-based generics pharmaceutical company operating in the dermatology, respiratory, cardiology, and oncology therapeutic areas. The company has 15 manufacturing facilities across four countries, of which nine are approved by the U.S. FDA.

Mr. Glenn Saldanha and family (through trusts) held 46.7% of the company as of Sept. 30, 2021.

Our Base-Case Scenario

Assumptions

- Glenmark's revenue to grow by 9%-10% in fiscal 2022 and 8%-9% in fiscal 2023.
- Glenmark to maintain focus on cost optimization and reasonable investments in R&D. This should help the company sustain EBITDA margins at 19%-19.5% in fiscals 2022 and 2023, compared with 19.8% in fiscal 2021.
- Glenmark to spend 9%-10% of revenue on R&D in fiscals 2022 and 2023, compared with 11.2% in fiscal 2021.
- Capital expenditure of INR6.5 billion-INR7 billion over this period, compared with INR7.8 billion in fiscal 2021.
- We expect the company will pay about 10% of its net profit as dividends in fiscals 2022 and 2023.

Based on these assumptions, we arrive at the following key metrics:

- FFO-to-debt ratio of 35%-40% in fiscal 2022 and exceeding 40% in fiscal 2023; compared with 28% in fiscal 2021.
- Debt-to-EBITDA ratio of 1.5x-2.0x in fiscal 2022 and less than 1.5x in fiscal 2023, compared with 2.4x in fiscal 2021.

Liquidity

We view Glenmark's liquidity as adequate. We expect the company's liquidity sources will exceed its uses by more than 1.5x over the 12 months ending Sept. 30, 2022, and net sources to remain positive even if EBITDA declines by 15%.

Glenmark has about US\$100 million available in undrawn revolving credit facilities, which will be sufficient to repay the company's FCCBs due in July 2022. Glenmark will remain prudent in its risk management, in our view. The company has fair banking relationships and its standing in capital markets is still developing when compared with peers at a similar rating level.

Principal liquidity sources include:

- Cash and short-term investments of INR14.3 billion as of Sept. 30, 2021.
- Cash FFO that we estimate at about INR16 billion over the 12 months ending Sept. 30, 2022.
- Available undrawn revolving credit facilities of US\$100 million.

Principal liquidity uses include:

- Debt maturities of about INR12 billion over the 12 months ending Sept. 30, 2022, including a bullet maturity of FCCBs in July 2022.
- Capital spending of INR6 billion-INR7 billion over the 12 months ending Sept. 30, 2022.
- Dividend payout of about INR900 million over this period.

Ratings Score Snapshot

Issuer Credit Rating: BB/Stable/--

Business risk: Weak

- Country risk: Intermediate
- Industry risk: Low
- Competitive position: Weak

Financial risk: Intermediate

- Cash flow/Leverage: Intermediate

Anchor: bb

Modifiers

- Diversification/Portfolio effect: Neutral (no impact)
- Capital structure: Neutral (no impact)
- Financial policy: Neutral (no impact)
- Liquidity: Adequate (no impact)
- Management and governance: Fair (no impact)
- Comparable rating analysis: Neutral (no impact)

Related Criteria

- General Criteria: Environmental, Social, And Governance Principles In Credit Ratings, Oct. 10, 2021
- General Criteria: Group Rating Methodology, July 1, 2019
- Criteria | Corporates | General: Corporate Methodology: Ratios And Adjustments, April 1, 2019
- Criteria | Corporates | General: Methodology And Assumptions: Liquidity Descriptors For Global Corporate Issuers, Dec. 16, 2014
- General Criteria: Country Risk Assessment Methodology And Assumptions, Nov. 19, 2013
- Criteria | Corporates | General: Corporate Methodology, Nov. 19, 2013
- General Criteria: Methodology: Industry Risk, Nov. 19, 2013
- General Criteria: Methodology: Management And Governance Credit Factors For Corporate Entities, Nov. 13, 2012
- General Criteria: Principles Of Credit Ratings, Feb. 16, 2011
- General Criteria: Stand-Alone Credit Profiles: One Component Of A Rating, Oct. 1, 2010

Ratings List

Upgraded

	To	From
Glenmark Pharmaceuticals Ltd.		
Issuer Credit Rating	BB/Stable/--	BB-/Stable/--

Certain terms used in this report, particularly certain adjectives used to express our view on rating relevant factors, have specific meanings ascribed to them in our criteria, and should therefore be read in conjunction with such criteria. Please see Ratings Criteria at www.standardandpoors.com for further information. Complete ratings information is available to subscribers of RatingsDirect at www.capitaliq.com. All ratings affected by this rating action can be found on S&P Global Ratings' public website at www.standardandpoors.com. Use the Ratings search box located in the left column.

Copyright © 2021 by Standard & Poor's Financial Services LLC. All rights reserved.

No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of Standard & Poor's Financial Services LLC or its affiliates (collectively, S&P). The Content shall not be used for any unlawful or unauthorized purposes. S&P and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P's opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P does not act as a fiduciary or an investment advisor except where registered as such. While S&P has obtained information from sources it believes to be reliable, S&P does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives. Rating-related publications may be published for a variety of reasons that are not necessarily dependent on action by rating committees, including, but not limited to, the publication of a periodic update on a credit rating and related analyses.

To the extent that regulatory authorities allow a rating agency to acknowledge in one jurisdiction a rating issued in another jurisdiction for certain regulatory purposes, S&P reserves the right to assign, withdraw or suspend such acknowledgment at any time and in its sole discretion. S&P Parties disclaim any duty whatsoever arising out of the assignment, withdrawal or suspension of an acknowledgment as well as any liability for any damage alleged to have been suffered on account thereof.

S&P keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain business units of S&P may have information that is not available to other S&P business units. S&P has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P reserves the right to disseminate its opinions and analyses. S&P's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.ratingsdirect.com (subscription), and may be distributed through other means, including via S&P publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.

STANDARD & POOR'S, S&P and RATINGSDIRECT are registered trademarks of Standard & Poor's Financial Services LLC.